Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Total Liabilities (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Total Liabilities readings, the most recent being $18.6 million for Q4 2025.

  • Quarterly Total Liabilities rose 2.74% to $18.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.6 million through Dec 2025, up 2.74% year-over-year, with the annual reading at $18.6 million for FY2025, 2.74% up from the prior year.
  • Total Liabilities hit $18.6 million in Q4 2025 for Terns Pharmaceuticals, up from $17.6 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $18.6 million in Q4 2025 and bottomed at $6.7 million in Q2 2021.
  • Average Total Liabilities over 5 years is $12.0 million, with a median of $12.7 million recorded in 2023.
  • The largest annual shift saw Total Liabilities plummeted 93.89% in 2021 before it surged 103.39% in 2023.
  • Terns Pharmaceuticals' Total Liabilities stood at $7.8 million in 2021, then increased by 29.82% to $10.1 million in 2022, then soared by 30.42% to $13.2 million in 2023, then skyrocketed by 37.33% to $18.1 million in 2024, then rose by 2.74% to $18.6 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Total Liabilities are $18.6 million (Q4 2025), $17.6 million (Q3 2025), and $15.2 million (Q2 2025).